Trial Profile
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 29 Jan 2018 Status changed from suspended to recruiting.
- 12 Jan 2017 New trial record